FDA approves combination SLT/YAG laser

The FDA has approved Quantel Medical’s Optimis Fusion integrated laser platform for cataract and glaucoma.

The system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption, and can be integrated with Quantel’s Vitra Monospot and Multispot pattern-scanning retina laser system.

“We are extremely excited to bring our breakthrough laser platform to the U.S. market,” said Jean-Marc Gendre, CEO of Quantel Medical.“The Optimis Fusion has proven to be a very attractive laser platform since introduction earlier this year in other markets. Driving the acceptance of this product introduction is the ability to combine a 532 nm mono-spot or multi-spot retina laser, a unique feature to Quantel’s laser line.”